MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT®, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced results from a ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT ®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the U ...

CARY, N.C. (WTVD) -- Chronic sinus sufferers can now bypass invasive surgery in the hospital and opt for a quick in-and-out procedure in their doctor's office. It's thanks to an innovative procedure ...

Intersect ENT, which focuses on products for patients with ear, nose and throat conditions, said a study dubbed ASCEND that evaluated its drug-coated sinus balloon for dilation of the frontal sinus ...

Acclarent, an Irvine-based maker of minimally invasive technologies for the ears, nose and throat sector, is being sold by parent Johnson & Johnson for $275 million to Integra LifeSciences Holdings ...

VenSure and Cube Join the Company’s Portfolio of Localized Drug Delivery Creating an Integrated Offering of ENT Technologies to Treat CRS As many as 1 in 8 adults in the United States suffer from CRS, ...